# Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)

> **NCT00092417** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 695 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Comparator: Varicella Zoster Virus Vaccine
- **BIOLOGICAL:** Comparator: Varicella Zoster Virus Vaccine

## Key facts

- **NCT ID:** NCT00092417
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2004-06
- **Final completion:** 2004-06
- **Target enrollment:** 695 (ACTUAL)
- **Last updated:** 2015-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092417, "Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00092417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*